- Capital Cube•4 months ago
Click here to see latest analysisPharmaxis Ltd. reports financial results for the quarter ended December 31, 2015.HighlightsGross margins narrowed from 4.57% to -126.60% compared to the same period last year, operating (EBITDA) margins now -465.67% from -465.84%.Earnings growth from operating margin improvements as well as one-time items.The table below shows the preliminary results and recent […] (Read more...) The post Pharmaxis Ltd. :PXS-AU: Earnings Analysis: Q2, 2016 By the Numbers appeared first on CapitalCube.
- PR Newswire•11 months agoPharmaxis Releases Successful Results of Phase 1 Clinical Trial for Boehringer Ingelheim Partnered Drug PXS-4728A
SYDNEY, Sept. 21, 2015 /PRNewswire/ -- Pharmaceutical company Pharmaxis (PXS.AX) today announced positive results for all primary and secondary endpoints from the phase 1 clinical trial of PXS-4728A, a drug that was recently acquired by Boehringer Ingelheim to develop as a treatment for cardiometabolic diseases such as Non-Alcoholic Steatohepatitis (NASH). PXS-4728A is a highly selective inhibitor of an enzyme and adhesion protein (SSAO/VAP-1 encoded by the AOC3 gene) which reduces inflammation and oxidative stress. The data confirmed the high oral bioavailability of PXS-4728A and most importantly, showed these low doses are efficacious in inhibiting the enzyme and cause a long lasting inhibition suggesting PXS-4728A can be dosed once a day.
Pharmaxis Ltd. (PXS.AX)
ASX - ASX Delayed Price. Currency in AUD
|Day's Range||0.29 - 0.30|
|52wk Range||0.20 - 0.41|
|1y Target Est||N/A|
Trade prices are not sourced from all markets
|P/E Ratio (ttm)||5.78|
|Avg Vol (3m)||324,308|
|Dividend & Yield||N/A (N/A)|